Medeon Biodesign Inc

ROCO:6499 (Taiwan)  
NT$ 50.50 (+1.2%) Jun 21
At Loss
P/B:
2.18
Market Cap:
NT$ 4.60B ($ 142.15M)
Enterprise V:
NT$ 2.86B ($ 88.45M)
Volume:
528.00K
Avg Vol (2M):
43.84K
Trade In:
Volume:
528.00K
At Loss
Avg Vol (2M):
43.84K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Medeon Biodesign Inc ( ROCO:6499 ) from 2014 to Jun 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Medeon Biodesign stock (ROCO:6499) PE ratio as of Jun 21 2024 is 0. More Details

Medeon Biodesign Inc (ROCO:6499) PE Ratio (TTM) Chart

To

Medeon Biodesign Inc (ROCO:6499) PE Ratio (TTM) Historical Data

Total 1224
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Medeon Biodesign PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-21 At Loss 2024-04-17 At Loss
2024-06-20 At Loss 2024-04-16 At Loss
2024-06-19 At Loss 2024-04-15 At Loss
2024-06-18 At Loss 2024-04-12 At Loss
2024-06-17 At Loss 2024-04-11 At Loss
2024-06-14 At Loss 2024-04-10 At Loss
2024-06-13 At Loss 2024-04-09 At Loss
2024-06-12 At Loss 2024-04-08 At Loss
2024-06-11 At Loss 2024-04-03 At Loss
2024-06-07 At Loss 2024-04-02 At Loss
2024-06-06 At Loss 2024-04-01 At Loss
2024-06-05 At Loss 2024-03-29 At Loss
2024-06-04 At Loss 2024-03-28 At Loss
2024-06-03 At Loss 2024-03-27 At Loss
2024-05-31 At Loss 2024-03-26 At Loss
2024-05-30 At Loss 2024-03-25 At Loss
2024-05-29 At Loss 2024-03-22 At Loss
2024-05-28 At Loss 2024-03-21 At Loss
2024-05-27 At Loss 2024-03-20 At Loss
2024-05-24 At Loss 2024-03-19 At Loss
2024-05-23 At Loss 2024-03-18 At Loss
2024-05-22 At Loss 2024-03-15 At Loss
2024-05-21 At Loss 2024-03-14 At Loss
2024-05-20 At Loss 2024-03-13 At Loss
2024-05-17 At Loss 2024-03-12 At Loss
2024-05-16 At Loss 2024-03-11 At Loss
2024-05-15 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-03-01 At Loss
2024-05-07 At Loss 2024-02-29 At Loss
2024-05-06 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss

Medeon Biodesign Inc (ROCO:6499) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.